Ilyang Pharm Cash Flow Conversion Efficiency

Latest as of June 2025: 0.009x

Ilyang Pharm cash flow conversion efficiency. Based on the latest financial reports, Ilyang Pharm (007570) has a cash flow conversion efficiency ratio of 0.009x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.26 Billion ≈ $1.53 Million USD) by net assets (₩239.41 Billion ≈ $162.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Ilyang Pharm (007570) total market value for the company's overall valuation and market capitalisation.

Cash Flow Conversion Efficiency of Ilyang Pharm (2003–2024)

Cash flow conversion efficiency of Ilyang Pharm from 2003 to 2024. This chart illustrates how Ilyang Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Ilyang Pharm stock price today for real-time trading data and today's change.

Ilyang Pharm Cash Flow Conversion Ratio Explained

Ilyang Pharm cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Ilyang Pharm Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ilyang Pharm ranked by their cash flow conversion efficiency. Review 007570 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.

Company	Cash Flow Conversion Efficiency
Vistin Pharma ASA OL:VISTN	-0.010x
Tai Tung Communication Co Ltd TW:8011	0.040x
Dimerix Ltd AU:DXB	3.087x
Arla Plast AB ST:ARPL	0.019x
Neuraxis, Inc. NYSE MKT:NRXS	-0.214x
Captor Therapeutics S.A. WAR:CTX	-0.346x
TWay Holdings KO:004870	-0.007x
DT Cloud Star Acquisition Corporation Units NASDAQ:DTSQU	-0.001x

Annual Cash Flow Conversion Efficiency for Ilyang Pharm (2003–2024)

The table below shows the annual cash flow conversion efficiency of Ilyang Pharm from 2003 to 2024. Also see Ilyang Pharm assets under control for a full breakdown of the balance sheet.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩241.58 Billion ≈ $163.71 Million	₩5.61 Billion ≈ $3.81 Million	0.023x	-65.79%
2023-12-31	₩196.41 Billion ≈ $133.10 Million	₩13.34 Billion ≈ $9.04 Million	0.068x	-33.76%
2022-12-31	₩291.85 Billion ≈ $197.79 Million	₩29.94 Billion ≈ $20.29 Million	0.103x	-58.41%
2021-12-31	₩271.76 Billion ≈ $184.17 Million	₩67.02 Billion ≈ $45.42 Million	0.247x	+5.08%
2020-12-31	₩244.92 Billion ≈ $165.98 Million	₩57.48 Billion ≈ $38.96 Million	0.235x	+44.44%
2019-12-31	₩222.74 Billion ≈ $150.95 Million	₩36.19 Billion ≈ $24.53 Million	0.162x	+54.17%
2018-12-31	₩209.88 Billion ≈ $142.23 Million	₩22.12 Billion ≈ $14.99 Million	0.105x	-25.94%
2017-12-31	₩210.98 Billion ≈ $142.98 Million	₩30.03 Billion ≈ $20.35 Million	0.142x	+14.64%
2016-12-31	₩217.35 Billion ≈ $147.30 Million	₩26.98 Billion ≈ $18.29 Million	0.124x	-34.96%
2015-12-31	₩211.00 Billion ≈ $142.99 Million	₩40.27 Billion ≈ $27.29 Million	0.191x	+87.97%
2014-12-31	₩183.46 Billion ≈ $124.33 Million	₩18.63 Billion ≈ $12.62 Million	0.102x	+714.91%
2013-12-31	₩183.88 Billion ≈ $124.61 Million	₩-3.04 Billion ≈ $-2.06 Million	-0.017x	-112.63%
2003-12-31	₩77.13 Billion ≈ $52.27 Million	₩10.08 Billion ≈ $6.83 Million	0.131x	--

About Ilyang Pharm

KO:007570 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$84.91 Million

₩125.30 Billion KRW

Market Cap Rank

#19682 Global

#1005 in Korea

Share Price

₩6990.00

Change (1 day)

-1.41%

52-Week Range

₩6960.00 - ₩8990.00

All Time High

₩95982.23